Dr. Rachel Tate uptoTate
2 years 7 months ago
Welcome to the "FDA-approved" team Bimekizumab. Dr. Armstrong shows MOA of IL17a and IL17f dual inhibition, and the important PASI scores showing 2/3 of pts clear by week 16. @RheumNow #RNL2024 @_AprilArmstrong https://t.co/KiTcVsGzpD
Dr. Rachel Tate uptoTate
2 years 7 months ago
Dr. April Armstrong shares a beautiful picture around pathophysiology in PsO/PsA, as demonstrated in a non-joint graphic below. "Consider the domains when choosing biologics." #RNL2024 @RheumNow @_AprilArmstrong https://t.co/2nUAUYZLL3
Dr. Antoni Chan synovialjoints
2 years 7 months ago
The different outcomes and response to treatment in males and females are related to sex differences in pain mechanisms and gender roles. Women report a higher BASDAI level, the ASDAS is equal in both sexes, Lihi Eder #RNL2024 @RheumNow https://t.co/7jjkgmmUg8
Richard Conway RichardPAConway
2 years 7 months ago
Radiographic changes are more common and severe in males with PsA. Over-weighting radiographic changes in your clinical reasoning will lead to missed diagnoses in women @lihi_eder @RheumNow #RNL2024 https://t.co/3OpMt7QaU8
TheDaoIndex KDAO2011
2 years 7 months ago
Did you know?! Remission criteria perform differently in men and women with rheumatic diseases; studies really do NOT account for this. – Dr. Eder #RNL2024 @rheumnow https://t.co/2JOTyD1GDZ
Richard Conway RichardPAConway
2 years 7 months ago
Differences in presentation of PsA in men and women. Crucial to incorporate this into your diagnostic formulation @lihi_eder @RheumNow #RNL2024 https://t.co/uvnU1ujCX7
TheDaoIndex KDAO2011
2 years 7 months ago
Picking the right tools to measure disease activity may be difficult because these tools may perform differently in men and women. The ASDAS show to differences between sexes but the BASDAI was significantly higher in women than in men. – Dr. Eder #RNL2024 @rheumnow https://t.co/KSBMrxio5P
Richard Conway RichardPAConway
2 years 7 months ago
Key take home points from @_AprilArmstrong on psoriatic disease @RheumNow #RNL2024 https://t.co/Svx9gNKBuR
TheDaoIndex KDAO2011
2 years 7 months ago
Potential board question: be able to differentiate between osteitis condensan ilii vs sacroiliitis. With osteitis condensan, the SI joint is normal, with no irregularity, erosions, or loss of joint space. Sclerosis is predominantly on the iliac bone @rheumnow #RNL2024 @rheumnow https://t.co/mimcdoufEE
TheDaoIndex KDAO2011
2 years 7 months ago
Men with PsA have more severe psoriasis, axial disease, high CRP, erosive disease compared to women, but women tend to have more pain. Delay to diagnosis in female patients are likely related to these differences- Dr. Eder #RNL2024 @rheumnow https://t.co/S9dzANITfH
Richard Conway RichardPAConway
2 years 7 months ago
Nice summary of data as to why IL-17 or IL-23 are generally favoured by dermatology for psoriasis @_AprilArmstrong @RheumNow #RNL2024 https://t.co/qfAn2AHilX
TheDaoIndex KDAO2011
2 years 7 months ago
Dr. Eder on gender differences – we need to move from gender blind to gender specific approach to treating our patients. There are biological, cultural, and social differences between males and females. #RNL2024 @rheumnow https://t.co/gnzU6FKIPR
Dr. Antoni Chan synovialjoints
2 years 7 months ago
Key takeaways when choosing therapies anti-TNFs, IL-17i, IL-23i, JAKs and TYK-2, in psoriasis. Think of skin, joint and spine involvement, April Armstrong #RNL2024 @RheumNow https://t.co/nUMmQk4xZq
Richard Conway RichardPAConway
2 years 7 months ago
Considerations in choosing a biologic in psoriatic disease from dermatology viewpoint @_AprilArmstrong @RheumNow #RNL2024 https://t.co/PHg0CBjTkC
Eric Dein ericdeinmd
2 years 7 months ago
#RNL2024 @RheumNow
@_AprilArmstrong: Deucravacitinib v Apremilast
Deucra: TYK2 inhibitor, approved for PsO (not yet PsA)
Superior to apremilast for skin disease (sPGA) https://t.co/NRnsm4cOum
